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Abstract
Sepsis is often characterized by an acute brain inflammation and dysfunction, which is associated 
with increased morbidity and mortality worldwide. Preventing cerebral leukocyte recruitment may 
provide the key to halt progression of systemic inflammation to the brain. Here we investigated the 
influence of the anti-inflammatory and anti-oxidant compound, sulforaphane (SFN) on 
lipopolysachharide (LPS)-induced cellular interactions in the brain.
The inflammatory response elicited by LPS was blunted by SFN administration (5 and 50 mg/Kg 
i.p.) 24 h prior to LPS treatment in WT animals, as visualized and quantified using intravital 
microscopy. This protective effect of SFN was lost in Nrf2-KO mice at the lower dose tested, 
however 50 mg/Kg SFN revealed a partial effect, suggesting SFN works in part independently of 
Nrf2 activity. In vitro, SFN reduced neutrophil recruitment to human brain endothelial cells via a 
down regulation of E-selectin and vascular cell adhesion molecule 1 (VCAM-1). Our data confirm 
a fundamental dose-dependent role of SFN in limiting cerebral inflammation. Furthermore, our 
data demonstrate that not only is Nrf2 in part essential in mediating these neuroprotective effects, 
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but they occur via down-regulation of E-selectin and VCAM-1. In conclusion, SFN may provide a 
useful therapeutic drug to reduce cerebral inflammation in sepsis.
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Introduction
Uncontrolled inflammation is now considered a major component of various widespread 
diseases including Alzheimer’s disease [1], stroke [2], cancer [3] and sepsis [4]. Whilst it is 
generally accepted that inflammation is not the primary cause of these diseases, it plays a 
key role in disease progression, tissue dysfunction and ultimately organ failure. Sepsis is an 
inflammatory condition involving a complex interaction of multiple pathways. It is the most 
common causes of death in hospitalized patients, which in part, is due to the susceptibility of 
the expanding aged population to infection, increased frequency of invasive procedures, and 
widespread bacterial antibiotic resistance [5, 6] and forecasts are predicting a rise to over 
one million cases annually by 2020 [1].
Endothelial dysregulation, coagulopathy with microvascular thrombosis, excessive vascular 
leak and increased leukocyte activation lie at the heart of tissue injury and organ failure 
during sepsis. When activated, leukocytes undergo a sequential pattern of interaction with 
vascular endothelial cells, characterized by rolling, adhesion and emigration into inflamed/
infected tissue [7]. This inflammatory response which is observed in sepsis [8] is caused 
within hours by peripheral inflammogens inducing an up-regulation of cell adhesion 
molecules on the surface of the endothelium (P-selectin, E-selectin, vascular cell adhesion 
molecule 1 [VCAM-1], and intercellular adhesion molecule 1 [ICAM-1]) and leading to 
increased adhesion, rolling, and transmigration of circulating leukocytes.
Over half of the cases of sepsis are due to gram-negative bacteria [9], in which endotoxin 
(lipopolysachharide [LPS]) is a key cell wall component. By interacting with host cell 
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receptors, such as monocyte/macrophage CD14 and toll-like receptor 4 (TLR4), LPS 
induces proinflammatory mediators e.g. eicosanoids and cytokines, such as tumor necrosis 
factor-α (TNF-α), interleukin 1 beta (IL-1β), IL-6 [10]. Cytokines are produced by several 
cell types, including neutrophils, monocytes, macrophages, lymphocytes, and endothelial 
cells [7]. They are released in response to inflammatory stimuli and are responsible for 
causing many of the physiological, metabolic and immunological responses associated with 
inflammation [8]. Despite these effects, therapies directed towards combating the pro-
inflammatory cytokines have been unsuccessful in the clinic. Additionally, patients that 
survive sepsis are sometimes left with long-term cognitive difficulties and neurological 
defects due to sepsis-associated encephalopathy, which occurs despite the protection 
provided by the blood-brain barrier [8]. Therefore, there is an urgent need for new and 
effective therapies to combat sepsis.
Sulforaphane (SFN) is a sulfur-based isothiocyanate found naturally in cruciferous 
vegetables such as broccoli, brussel sprouts, cabbage and cauliflower [11]. SFN has been 
shown to induce anti-oxidative mechanisms, and protect against cell inflammatory stress via 
activation of the NF-erythroid 2-related factor 2 (Nrf2) transcription factor [12]. Under basal 
conditions, Nrf2 is anchored to the cytoplasm by Kelch-like ECH-associated protein 1 
(Keap1). Through interactions with the cysteine residues of Keap1, SFN may induce the 
release of Nrf2 allowing for its nuclear localization where it binds to the antioxidant 
response element (ARE) in the promoter region of a variety of different genes involved in 
antioxidant protection, including heme oxygenases and superoxide dismutase [12, 13]. 
Although it has been shown that SFN may have anti-inflammatory effects, these anti-
inflammatory mechanisms are less well-understood, especially within the context of the 
cerebral microvasculature. SFN treatment reduces monocyte adhesion to primary endothelial 
cells via inhibition of nuclear factor kappa B (NF-κB) activation [15] and treatment of 
cultured Raw 264.7 macrophages with SFN suppresses LPS-induced nitric oxide generation, 
prostaglandin E2 (PGE2) production, TNF-α secretion, inducible nitric oxide synthase 
(iNOS) and Cox-2 expression [16]. SFN pre-conditioning has also been shown to protect 
against blood brain barrier (BBB) disruption and neurological deficits in a rodent model of 
stroke [17]. As such, SFN treatments or dietary supplements may prove effective in 
protecting against pathological leukocyte recruitment to the brain.
In this study, we utilized in vivo and in vitro models of leukocyte recruitment to investigate 
the potential of SFN to reduce cerebral leukocyte recruitment and inflammatory activation. 
Our results support the premise that SFN plays an important role in protecting the cerebral 
vasculature from inflammatory insults. We also show for the first time that following 
systemic inflammatory insults, SFN exerts its protective actions on human cerebral 
endothelial cells (HBMEC-3) by inhibiting VCAM-1 and E-selectin expression. 
Furthermore, this protective effect of SFN was lost in Nrf2-KO mice at the lower dose 
tested, however 50 mg/Kg SFN revealed a partial effect, suggesting SFN works in part 
independently of Nrf2 activity. In conclusion, SFN may provide a useful therapeutic drug to 
reduce cerebral inflammation in sepsis.
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All reagents were obtained from Sigma-Aldrich, St Louis, MO, USA, unless stated 
otherwise.
Animal experiments
Drugs and reagents—L-sulforaphane (SFN, 5 mg/kg and 50 mg/kg) was dissolved in 
corn oil for intraperitoneal (i.p.) injection 24 h prior to LPS/vehicle injection as previously 
described [18]. LPS (Escherichia coli serotype 0111:B4. 0.5 mg/Kg,) was dissolved in saline 
for i.p. injection 4 h prior to imaging of the cerebral microcirculation. Rhodamine 6G was 
dissolved in de-ionized water for i.v. injection.
Animals—Male wild-type (WT) C57BL/6J mice and Nfe2l2tm1Ywk knockout (Nrf2-KO) 
mice, 25–35g, 12–18 weeks old, were obtained from The Jackson Laboratory (Bar Harbor, 
ME, USA) and maintained on a 12 hour (h) light-dark cycle during which room temperature 
was maintained at 21– 23°C, and had access to standard chow pellets and water ad libitum. 
Experimental procedures were reviewed and approved by Louisiana State University Health 
Sciences Center-Shreveport (LSUHSC-S) Institutional Animal Care and Use Committee, 
and were performed according to the criteria outlined in the National Institutes of Health 
guidelines. Animals were randomly assigned to treatment groups (n = 6 animals per group, 
group size determined with reference to our previous studies in this model [7].
Intravital fluorescence microscopy (IVM)
Animals were anesthetized with an i.p. injection of ketamine (150 mg/kg) and xylazine (7.5 
mg/kg) and the jugular vein was cannulated for intravenous (i.v.) administration of 
rhodamine 6G. Core body temperature was maintained at 37 ± 0.5°C. A craniotomy was 
performed and the dura matter was not removed as fluorescently labeled blood cells were 
easily observed and intracranial pressure was well maintained in the absence of this 
procedure [20]. Artificial cerebrospinal fluid (NaCl 131.9 mM, CaCl2 1.26 mM, 
CaCl2·2H2O 1.26 mM, KCl 2.95mM, MgCl2·6H2O 0.64 mM, MgCl2 0.5 mM, (NH2)2CO 
6.69 mM, C6H12O6 3.69 mM) was placed on the cranial opening. The preparation was 
allowed to equilibrate for 30 minute (min) before visualization of cerebral microcirculation 
using a 40 X water-immersion objective attached to a Xanophot IVM microscope 
(HLX64610; Nikon, Melville, NY, USA). Rhodamine 6G (100 µl, 0.02% v/w in saline, i.p) 
was used to fluorescently label leukocytes. Sections of un-branched pial post capillary 
venules 100 µm in length and 30–70 µm in diameter (omitting analysis of dura vessels which 
are typically 20 µm. [20]) were randomly selected and recordings made for offline analysis 
using a three charge coupled device color video camera (Hitachi, Woodbury, NY, USA). 
Rolling velocity (determined from the time required for a leukocyte to roll a given distance 
along the length of a venule, and is reported as µm/sec), and adhesion (cells that remained 
adherent for 30 seconds (sec) or longer, and expressed as the number of cells per millimeter 
of the venular surface, assuming the vessel to be cylindrical as previously described [19]) 
were assessed offline.
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Brain homogenates and MPO standards were placed onto a 96-well plate, and 200 µl of o-
dianisidine solution and 10 µl of 0.1 % H2O2 were added. Absorbance was read after 5 min 
at 405 nm and expressed as units per mg (U/mg) of wet tissue.
Cytometric bead array (CBA)
Serum samples were collected from experimental animals and quantitative analysis of 
multiple cytokines, including: IL-6, IL-10, monocyte chemoattractant protein-1 (MCP-1), 
interferon gamma (IFN-γ), TNF-α, and IL-12(p70) was performed using a CBA Mouse 
Inflammation Kit (BD Biosciences, San Jose, CA, USA) as per the manufacturer’s 
instructions. A dual laser FACSCalibur (BD Biosciences), with CellQuest pro (BD 
Biosciences) software was used for acquisition and results were analyzed and quantified 
with reference to the standard curve using FCAP Array software (version 3, Soft Flow Inc, 
St. Louis Park, MN, USA).
Human neutrophil isolation
Blood collection and neutrophil isolation was performed with ethical approval from the 
LSUHSC-S Institutional Review Board (STUDY00000261). Blood samples (50ml) were 
taken from healthy individuals aged 18 – 45 years, with no history of recent acute or chronic 
illness and non-steroidal anti-inflammatory drug (NSAID) free 2 weeks prior to blood 
collection at LSUHSC-S. Blood was collected from the anterior cubital fossa with a 21G 
needle, using 1:10 Acid Citrate Dextrose Solution anticoagulant. All samples were collected 
and processed within 4 h. Neutrophils were isolated using dextran sedimentation and 
histopaque 1077 Ficoll gradient-centrifugation as previously described [21].
Flow chamber assay
Human brain endothelial cell line (HBMEC-3) were seeded in IBIDI µ-Slide VI04 flow 
chambers and cultured for two days until confluent. The cells were treated with SFN (1, 10 
and 100 µM) or 0.3% Dimethyl sulfoxide vehicle control 24 h prior to the addition of LPS 
(500 ng/ml) or saline vehicle control. HBMEC-3 monolayers were stimulated with LPS for 
4 h before commencing flow. Neutrophils were fluorescently labeled with 5 µM 
CellTracker™ Red CMTPX dye (Life Technologies, Grand Island, NY, USA) for 25 min at 
room temperature. Neutrophils were then centrifuged at 400 x g for 10 min and resuspended 
to 1×106 cells/ml in Dulbecco’s phosphate-buffered saline (DPBS) with 0.1% BSA before 
perfusing over HBMEC-3 monolayers at 0.5 dyne/cm2 for 10 min. Leukocyte endothelial 
interactions were viewed under an Olympus IX71 inverted microscope (x20 objective. 
Olympus, Saucon, PA, USA), with TRITC filter and 100W high pressure mercury bulb light 
source. At least 5 random fields per treatment were recorded for offline analysis, using a 
Sony 3CCD DSP color video camera (Sony, New York, NY, USA), for 10 sec each. Rolling 
velocity (velocities of 20 consecutive leukocytes in the field of focus were determined by 
measuring the time required to travel a distance of 100 µm. Reported as µm/sec) and 
adhesion (those cells that had remained stationary for 10 sec or longer) were quantified 
during offline analysis as previously described [19].
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HBMEC-3 seeded in IBIDI µ-Slide VI0.4 flow chambers monolayers were treated with SFN 
(1, 10 and 100 µM) or vehicle 24 h prior to the addition of LPS (500 ng/ml for 4 h). Cells 
were washed with PBS and fixed with 4% Paraformaldehyde (PFA) for 10 min before 
blocking with PBS + 1% BSA, 10% goat serum and 100 mM glycine. Cells were then 
incubated with primary antibodies for P-selectin (ab54427, 1:100 Abcam, Cambridge, MA, 
USA,), E-selectin (BBA16, 1:200, R&D systems, Minneapolis, MN, USA), or vascular cell 
adhesion molecule-1 (VCAM-1, SC1504R, Santa Cruz Biotechnology, Dallas, TX, USA 
1:200) in PBS + 1% BSA overnight at 4°C. A Cy5.5 conjugated goat anti-mouse IgG 
(ab6947 Abcam) or goat anti-rabbit, alexafluor 488 (ab150077, Abcam) both at 1:200 was 
used as a secondary antibody and cells were mounted in vectasheild + DAPI nuclear stain. 
Staining was visualized using a using a Nikon Eclipse inverted microscope with Nikon 
Elements acquisition software (Nikon, Melville, NY, USA), and was quantified using 
ImageJ software (NIH) and expressed as mean pixel intensity of adhesion molecule 
expression, normalized to DAPI expression.
NF-κB activation was investigated in HBMEC-3 cells fixed and permeabilized in ice cold 
acetone before blocking and staining for phosphorylated NF-κB p65 (rabbit anti-NF-kB p65 
phospho-S536, ab86299, Abcam, 1:100 in PBS + 1% BSA) for 2 h. Cells were washed with 
PBS and incubated with goat anti-rabbit alexafluor 488 conjugated secondary (ab150077, 
1:200, Abcam). Slides were washed with PBS and mounted with vectasheild + DAPI nuclear 
stain. Co-localization of DAPI and alexafluor 488 staining was visualized using a using a 
Nikon Eclipse inverted microscope with Nikon Elements acquisition software. Nuclear mean 
pixel intensity normalized to area was used to quantify nuclear levels of NF-κB using 
ImageJ software (NIH).
Nrf2 transcription factor activation
To investigate Nrf2 activation and nuclear localization in HBMEC-3 cells treated with SFN 
(1, 10 and 100 µM) 24 h prior to stimulation with LPS (10 µg/ml, 4 h), nuclear fractions 
were isolated using Active Motif Nuclear extract kit (Active Motif, Carlsbad, CA, USA). 
Nrf2 activity was then assessed in 5 µg nuclear protein using TransAM® Nrf2 transcription 
factor activation assay (Active Motif) as per the manufacturer’s instructions.
Superoxide assay
To study the effect of SFN treatment on endothelial and neutrophil oxidative state following 
LPS stimulation (500 ng/ml 4h), CM-H2DCFDA oxidative stress indicator (Life 
Technologies) was used and fluorescence emission at 525 nm measured over 30 min. 
Briefly, HBMEC-3 cells grown to confluence in 96-well plates were pre-treated with SFN or 
vehicle for 24 h before being incubated with 5 µM of the cell permeable CM-H2DCFDA dye 
for 30 min. 5×105 neutrophils in 100 µl PBS + 1% BSA were added to 96-well plates, 
blocked with PBS + 1% BSA overnight. Baseline readings were taken using a Biotech 
Synergy H1 hybrid plate reader (BioTeK, Winooski, VT, USA) at 37°C excitation 490 nm 
emission 520 nm. Neutrophils were then stimulated with LPS (500 ng/ml) and emission was 
measured over 30 min. Results expressed as mean maximum relative light units.
Holloway et al. Page 6














Results from intravital microscopy experiments were confirmed to follow a normal 
distribution using Kolmogorov-Smirnov test of normality with Dallal-Wilkinson-Lillie for 
corrected p value. Data that passed the normality assumption was analyzed using Student’s 
t-test or ANOVA with Bonferroni post hoc test. Data that failed the normality assumption 
were analyzed using the non-parametric Mann-Whitney U test. Analysis was conducted 
using GraphPad Prism5 software. Data are reported as means +/− standard errors of the 
mean. Differences were considered statistically significant at a value of p < 0.05.
Results
SFN protects against LPS-induced cellular responses in the cerebral microcirculation
Previously we have shown that i.p. administration of LPS triggers a time-dependent effect on 
cellular responses in the brain [8]. Based on these findings, LPS was systemically 
administered for 4 h with and without SFN, in order to assess the therapeutic potential of the 
isothiocyanate. Using intravital fluorescence microscopy, we were able to visualize and 
quantify changes in leukocyte behavior within pial vessels, showing a significant (p < 0.001) 
decrease in leukocyte rolling velocity and an increase in leukocyte adhesion following LPS 
administration (Figure 1). Pre-treatment with SFN in the absence of an inflammatory 
stimulus was found to have no effect on any of the leukocyte recruitment parameters 
measured (Figure 1E+F). However, SFN (5 and 50 mg/Kg) significantly increased the LPS-
induced leukocyte rolling velocity and reduced leukocyte adhesion (p < 0.001. Figure 1E
+F).
SFN modulates inflammatory markers
Table 1 demonstrates the effect of SFN treatment on circulating levels of cytokines. LPS 
induced an elevation in pro-inflammatory cytokines: IFN-γ IL-6, MCP-1 and TNF-α, with 
no effect on the anti-inflammatory cytokine IL-10. SFN (5 mg/Kg) decreased levels of IFN-
γ MCP-1 and TNF-α, and increased IL-10 levels. These effects were also mirrored in 
animals treated with the higher dose of SFN (50 mg/Kg), coupled also with a decrease in 
IL-6 levels. There was no difference in IL-12 levels in any of the groups. We also found a 
significant increase in the same four cytokines in whole brain homogenates (Table 2) 
following LPS, along with a marked increase in MPO (Table 2). SFN treatment was found to 
reduce the LPS induced increase in brain inflammatory cytokines whilst also elevating IL-10 
expression and reducing MPO levels. (LPS: 4.16 ± 0.28 U/mg; SFN (5 mg/Kg)+LPS: 2.68 
± 0.35; SFN (50 mg/Kg)+LPS: 1.73 ± 0.11 U/mg).
Dose dependent effect of SFN in Nrf2-KO animals
To investigate whether the observed reduction in LPS-induced leukocyte adhesion was due 
to activation of Nrf2 anti-inflammatory and anti-oxidative pathways, SFN was given to 
Nrf2-KO mice. Nrf2 gene deletion afforded no difference in the inflammatory response 
associated with LPS, when compared to the WT counterparts (Figure 1+2). Low dose of 
SFN (5 mg/Kg) treatment did not influence leukocyte rolling velocity or adhesion in these 
Nrf2-KO animals (Figure 2A+B). However, the higher SFN dose (50 mg/Kg) increased 
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leukocyte velocity and decreased cellular adhesion (40%) in the brain. LPS produced an 
increase in the number of rolling cells (cell flux) in WT and Nrf2-KO vs. saline, with SFN 
having no effect (data not shown).
SFN moderates human neutrophil-endothelial cell interactions
In order to establish whether SFN treatment was effective in reducing recruitment of human 
neutrophils, in vitro experiments were conducted flowing isolated human neutrophils over 
LPS activated HBMEC-3 cells, under conditions relevant to venous physiological shear 
rates. HBMEC-3 cells stimulated with LPS (500 ng/ml) for 4 h (a point that allows sufficient 
time for de novo synthesis of adhesion molecules [22].) provoked a marked decrease in 
neutrophil rolling velocity and an increase in the number of adherent cells (Figure 3A–E). 
Treatments with both 10 and 100 µM SFN had no effect on the number of leukocytes rolling 
in LPS treated mice, but affected leukocyte adhesion (Figure 3D+E).
Numerous studies have shown that the activation of NF-κB is essential for the 
transcriptional regulation of chemotactic cytokines and vascular adhesion molecules that are 
critically involved in leukocyte adhesion to endothelium [15]. Thus, we determined the LPS-
induced activation of NF-κB signaling by confocal microscopic examination of NF-κB p65 
nuclear translocation. Exposure of HBMEC-3 cells to LPS for 4 h increased NF-κB nuclear 
localization indicating the induction of NF-κB-regulated gene expression (Figure 3F+G). 
Whilst no significant reduction in NF-κB activation was seen with 1 µM or 100 µM SFN 
treatment, 10 µM resulted in a significant (p < 0.05) decrease in nuclear fluorescence 
intensity compared to control (Figure 3H). These results suggest that SFN may inhibit 
inflammation by suppressing NF-κB signaling in a dose dependent fashion.
SFN treatment reduces LPS-induced expression of endothelial adhesion molecules
Cell adhesion molecules play an important role during inflammation, and their expression in 
endothelial cells is a pre-requisite for adhesion of neutrophils. Therefore, the effects of SFN 
on LPS-induced expression of E-selectin, P-Selectin, ICAM-1 and VCAM-1 were assessed 
by immunofluorescent staining (Figure 4). Unstimulated cells expressed low levels of the 
adhesion molecules, however, LPS treatment significantly induced the expression of 
HBMEC-3 E-selectin and VCAM-1. There was little effect on ICAM-1 expression, and 
whilst LPS induced a trend towards increased P-selectin expression, it was not statistically 
significant (data not shown). SFN treatment of 10µM was found to significantly reduce the 
LPS-induced expression of E-selectin and VCAM-1 (Figure 4A+C), with no statistically 
significant effects being observed on ICAM-1 and P-selectin expression (data not shown).
SFN reduces endothelial cell oxidative state
Oxidative stress is a key pathological factor local and systemic inflammatory pathologies. 
Considering that SFN has previously been shown to induce anti-oxidative enzyme 
expression via Nrf2 activation both in vivo and in vitro [23], we investigated the influence of 
SFN treatment on Nrf2 activation in the context of LPS challenge. In nuclear fractions from 
cortical homogenates of LPS challenged WT mice, no changes in Nrf2 activation was 
detected across all treatments (data not shown). However, in HBMEC-3, whilst LPS 
treatment alone had no influence on Nrf2 activation, all concentrations of SFN tested were 
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found to induce significant activation and nuclear translocation of Nrf2, as indicated by 
enhanced transcription factor activity in nuclear extracts (Figure 5A).
To correlate the neuroprotective effect of SFN with its ability to induce Nrf2, we measured 
ROS production from HBMEC-3 using the fluorescent oxidative stress indicator CM-
H2DCFDA. LPS treatment (500 ng/ml, 4h) was found to induce significant superoxide 
production from both neutrophils and HBMEC-3. A similar response was seen in both cell 
types, with 24 h pretreatment with SFN (10 and 100 µM) significantly inhibiting LPS-
induced ROS production (Figure 5B+C).
Discussion
Sepsis is an inflammatory condition involving a complex interaction of multiple pathways. It 
is the most common cause of death in hospitalized patients, and forecasts are predicting a 
rise to over one million cases annually by 2020 [6]. Systemic inflammatory responses in 
sepsis can trigger a diffuse or multifocal cerebral dysfunction even in the absence of any 
direct brain injury or infection, this is particularly evident in e.g. sepsis-associated 
encephalopathy (SAE). Thus, the array of sepsis-related complications may lead to multiple 
organ failure and ultimately death [6]. Efficient anti-inflammatory strategies are therefore 
required in order to provide therapeutic benefit to patients.
SFN, which is found at high levels in broccoli, is currently one of the most promising natural 
compounds for clinical implementation [24]. The anti-carcinogenic effects of high doses of 
SFN are well characterized. Recently it has been reported that SFN can penetrate BBB and 
exert neuroprotective effects in in vitro and in vivo models of neurological disorders [17, 
24], however the protective role of SFN on leukocyte trafficking within the context of the 
brain remains elusive. Here, using an animal model of endotoxaemia, we reveal a crucial 
inhibitory role of SFN in modulating leukocyte trafficking in the cerebral microcirculation. 
Our data show that Nrf2 gene deletion afforded no difference in the inflammatory response 
associated with LPS, when compared to the WT counterparts, and that SFN works through 
additional mechanisms other than Nrf2, since SFN’s influence over leukocyte recruitment 
was only in part abolished at the higher dose tested in Nrf2-KO animals. Furthermore, 
experiments using HBEMC-3 cells and human neutrophils, demonstrated protective actions 
of SFN following LPS challenge via down regulation of E-selectin, and VCAM-1, and a 
decrease in pro-inflammatory cytokines and ROS production.
Leukocyte recruitment to an inflamed site is an important facet of the inflammatory 
response. Leukocytes undergo a complex process whereby they tether, roll, adhere, spread 
and finally transmigrate through the endothelium [24]. This process is predominantly 
mediated by several intracellular signaling events that ultimately up-regulate the expression 
of pro-inflammatory cyokines, such as MCP-1, and adhesion molecules, including 
VCAM-1, ICAM-1, and P- and E-selectin [25]. These chemokines and adhesion molecules 
play key roles in the firm adhesion of leukocytes to activated endothelial cells [15]. 
However, excessive or inappropriate leukocyte accumulation in tissues contributes to a 
number of pathologic conditions such as stroke, myocardial infarction and sepsis. SFN has 
previously been shown to protect against liver injury following intestinal ischemia 
Holloway et al. Page 9













reperfusion (I/R) injury via Nrf2 signaling, markedly reducing liver tissue MPO activity, 
which is indicative of reduced neutrophil recruitment [26]. In the brain, Schachtele et al., 
[27] have demonstrated SFN to reduce macrophage and neutrophil brain infiltration and 
microglial activation in active viral brain infection. However, the present study is the first to 
directly quantify the influence of SFN treatment on cerebral leukocyte recruitment following 
systemic inflammatory challenge. SFN pre-treatment had a potent protective influence on 
the cerebral microvascular events induced by LPS, being effective in increasing leukocyte 
rolling (no affect on cell flux) and abrogating leukocyte adhesion and reducing MPO levels. 
The dose of LPS used here in our study was relatively low. This dose was chosen 
deliberately to activate the vasculature without causing either mortality or a drastic decrease 
in microvascular perfusion, as is seen at higher doses and which would complicate the 
inflammatory response [8].
Sepsis is associated with an excessive production of cytokines (including TNF-α, IL-6, and 
IL-1β), as well as activation of complement and coagulation cascades following activation of 
immune cells by endotoxin and other pathogen components [8]. TNF-α increases BBB 
permeability and the proinflammatory actions of IL-1β and IL-6 in the brain are well 
documented [28]. Here, LPS induced an increase in circulating pro-inflammatory cytokines 
(TNF-α, IL-6, IFNγ and MCP-1), which were inhibited when SFN was administered (along 
with upregulation of IL-10).
Recent studies have demonstrated that the Nrf2/ARE pathway is involved in immune and 
inflammatory processes, and SFN exerts protective effects via Nrf2 activation, which, under 
basal conditions, is anchored to the cytoplasm by Keap1. Through interactions with the 
cysteine residues of Keap1, SFN may induce the release of Nrf2 allowing for its nuclear 
localization where it binds to the antioxidant response element in a variety of different genes 
[11–13]. As such, in order to establish whether the observed influence over cerebral 
leukocyte recruitment was dependent on Nrf2 activation, we conducted experiments using 
Nrf2-KO mice. In absence of Nrf2, the lower dose of SFN treatment was found to be 
ineffective in reducing LPS-induced cerebral leukocyte recruitment (i.e. no cerebral 
leukocyte adhesion in WT mice). These findings concur with other studies that attribute the 
antioxidant and anti-inflammatory effects of SFN via the Nrf2/ARE pathway [29, 30]. The 
dependence of SFN’s anti-inflammatory effects on Nrf2 observed here are also supported in 
investigations by Zakkar et al., [18] who demonstrate SFN to suppress p38 activation and 
VCAM-1 expression at athero-susceptible sites in the aorta of WT mice, yet not in Nrf2-KO 
mice. However, we also found that at the higher dose of SFN, the SFN-mediated inhibition 
of cerebral inflammation was in part independent of the Nrf2/ARE pathway. These findings 
are supported by other groups describing Nrf2 independent effects of SFN in e.g. in cycle 
arrest and apoptosis, and inhibition of angiogenesis, histone deacetylases and cytochrome 
P450 [31]. Recently Greaney et al., 2015 focused studies on inflammasomes, as these have 
an important role in cytosolic innate immune sensing and pathogen response. They found 
that SFN-mediated inhibition of inflammasomes is also independent of Nrf2 [31]. Other 
evidence points to SFN reacting directly with other cellular targets such as toll like receptor 
4 (via the suppression of both ligand-induced and ligand-independent oligomerization of 
TLR4) [32] and tubulin [33]. Jackson and Singletary also showed high SFN doses (≥ 100 
µmol/l) have mammary cancer suppressive actions involving mitotic cell cycle arrest and 
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linked to the disruption of normal tubulin polymerization and possible effects on 
microtubule dynamics at lower SFN doses [34]. Furthermore, it has also been shown that 
SFN ameliorates skin blistering via Nrf2-dependent and -independent pathways [35]. These 
findings demonstrate the complex nature of SFN and its ability to mediate its anti-
inflammatory and anti-oxidant via various mechanisms.
It is known that local and temporal variations in adhesion molecule expression, such as E- 
and P-selectin, occur in response to LPS [36, 37]. Furthermore, constitutive and LPS-
induced expression of ICAM-1 and VCAM-1 are relatively low in the brain, and the kinetics 
and relative up-regulation of these adhesion molecules varies between tissues [7]. Therefore, 
having demonstrated the protective effects of SFN treatment in suppressing cerebral 
leukocyte recruitment in vivo, we next used the flow chamber assay to assess whether SFN 
treatment may also prove beneficial in reducing leukocyte-endothelial interactions in human 
cells, and if so whether the anti-inflammatory effect may be mediated by the inhibition of 
adhesion molecules. Thus, investigations were made using isolated human neutrophils and 
HBMEC-3s in an LPS-activated leukocyte recruitment assay under physiological flow. 
Previously, SFN has been shown to reduce low density lipoprotein-induced endothelial 
dysfunction, via inducing Nrf2, while suppressing NFκB activation and ICAM-1, VCAM-1, 
and E-selectin expression [38]. Furthermore SFN reduced TNF-α-induced VCAM-1 and 
MCP-1 expression in endothelial cells [39] and TNF-α induced adhesion of monocytes [15]. 
These studies used human umbilical cord vein endothelial cells, however in the present study 
we investigated anti-inflammatory and anti-oxidative influence of SFN in an endothelial cell 
line relevant to the unique cells of the cerebral microcirculation (i.e. HBMEC-3). In 
HBMEC-3, SFN reduced LPS-induced NF-κB activation, as demonstrated by nuclear 
localization of the phosphorylated p65. Further to the suppression observed in the present 
study, SFN also interacts with thiol groups to impair redox-sensitive DNA binding and 
transactivation of NF-κB, via binding to essential Cys residues, or NF-κB related redox 
regulators [16]. Correlating with decreased NF-κB activation, our studies showed reduced 
cell surface expression of E-selectin and VCAM-1, along with suppressed LPS-induced 
neutrophil adhesion under flow conditions. As was found in vivo, SFN treatment had no 
inhibitory effect on leukocyte rolling, furthermore P-selectin and ICAM-1 expression was 
found to be unaffected by SFN treatment, suggesting SFN intervention in cerebral leukocyte 
recruitment is via a suppression of VCAM-1 and E-selectin only.
Activated neutrophils may release large amounts of ROS in a respiratory burst, inducing a 
high level of oxidative stress, a key pathological factor in local and systemic inflammatory 
pathologies. This oxidative stress has been implicated in stress, and furthermore, the 
cerebrovasculature has been demonstrated to be a critical target of oxidative stress in 
pathological disorders of the brain, but may also be important source of ROS itself [40]. 
Vascular-derived oxidative stress is a major factor involved in initiating and promoting 
pathophysiology in a number of disorders of the brain, a process that is evident under 
inflammatory conditions [40]. Such events can be particularly detrimental in the brain, 
which lacks robust antioxidant defenses [41]. The neuronal membrane is largely made up of 
polyunsaturated fatty acids, which are highly susceptible lipid peroxidation [40], 
additionally ROS accumulation causes altered assembly of the tight junctions, breakdown of 
the extracellular matrix and loss of BBB integrity [40]. Nrf2 plays a key role in defense 
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against oxidative stress, and as such we investigated the influence of SFN treatment over 
Nrf2 activation and HBMEC-3 oxidative state, as quantified by CM-H2DCFDA 
fluorescence. Whilst in brain homogenates from experimental animals, no differences in 
Nrf2 transcription factor activation was detected, potentialy due to the numerous cell types 
present in the crude homogenate, SFN was found to activate Nrf2 at all concentrations tested 
in HBMEC-3, and reduce ROS production at both 10 and 100 µM following LPS challenge 
(500 ng/ml). SFN (10 and 100 µM) also reduced ROS production from neutrophils post-LPS 
challenge. Thus, SFN may be beneficial in promoting anti-oxidative mechanisms in the 
cerebral microcirculation to combat inflammatory increase in damaging ROS.
Blood born cells, the endothelium, resident perivascular cells and parenchymal cells can all 
influence the inflammatory microenvironment and regulate leukocyte recruitment. In the 
present study we demonstrate that SFN can have a direct effect on the endothelium by 
reducing leukocyte recruitment, an effect which was confirmed by our results showing the 
anti-inflammatory and anti-oxidative effects of SFN in vitro on HBMEC-3s. Nguyen et al., 
have demonstrated SFN to have beneficial anti-inflammatory effects on leukocytes, reducing 
NF-κB phosphorylation 50% [42] whilst SFN has also previously been demonstrated to be 
able to cross the BBB and to accumulate in cerebral tissues [43]. Indeed, SFN treatment has 
been demonstrated to beneficially effect brain resident cells both in vivo and in vitro [27] 
and provides a promising therapeutic candidate for the treatment of neuro-inflammatory 
diseases, in that it may have protective effects not only via anti-inflammatory and anti-
oxidative actions on vascular elements and leukocytes (as demonstrated in the present study) 
but may also influence brain resident cells.
In summary, the present study shows for the first time a fundamental role of SFN in limiting 
leukocyte endothelial cell interactions in the cerebral microvasculature following a systemic 
inflammatory challenge. The protective effects of SFN on cerebral vascular inflammation 
may be, at least in part, independent of Nrf2/ARE pathway and associated with the NF-κB 
pathway, which in turn leads to a via down-regulation of E-selectin and VCAM-1 (Figure 6). 
These findings provide evidence suggesting that SFN may be a novel agent to protect the 
cerebral vasculature against LPS-induced inflammation and dysfunction seen in sepsis.
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Figure 1. SFN pre-treatment reduces LPS-induced inflammatory cell recruitment into the brain
A) the chemical structure of SFN. B-D) representative video stills of cerebral microvessels 
following B) saline treatment, C) LPS treatment (0.5 mg/kg, i.p, 4 h) and D) LPS treatment 
with 24 h SFN pretreatment (50 mg/Kg). E-G) Leukocyte recruitment in the cerebral 
microcirculation of C57BL/6J mice following LPS injection (0.5 mg/kg, i.p) and 24 h saline 
vehicle or SFN pretreatment (5 or 50 mg/Kg) was quantified in terms of: E) rolling velocity 
(µm/sec), and F) adhesion (cells stationary for 30 sec or longer per mm2). Scale bar = 20 µm. 
Data are mean ± SEM of 6 mice per group. *p < 0.05 **p < 0.01 & ***p < 0.001 vs. 
saline. ###p < 0.0001 vs. LPS.
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Figure 2. Dose dependent effect of SFN in Nrf2-KO animals
Leukocyte recruitment in the cerebral microcirculation of Nrf2-KO mice following LPS 
injection (0.5 mg/kg, i.p) and 24 h saline vehicle or SFN pretreatment (5 or 50 mg/Kg) was 
quantified in terms of: A) rolling velocity (µm/sec) and B) adhesion (cells stationary for 30 
sec or longer per mm2). Data are mean ± SEM of 5–6 mice per group. *p < 0.05 & ***p < 
0.0001 vs. saline. #p < 0.05 vs. LPS.
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Figure 3. Effects of SFN on Human Neutrophil-Endothelium Interaction
HBMEC-3 cells were treated with saline or 500 ng/ml LPS for 4 h. A-E) human neutrophils 
were perfused over the stimulated endothelial cells under physiological flow to assess the 
influence of 24 h saline or SFN (1, 10 or 100 µM) pre-treatment on human neutrophil 
recruitment. A-C) Representative x20 video stills of fluorescently labeled neutrophils 
adhering to HBMEC-3 monolayers, scale bar = 100 µm. Neutrophil-endothelial cell 
interactions were quantified in terms of D) rolling velocity (µm/sec) and E) adhesion (cells 
stationary for 10 sec or longer per mm2). F+G) LPS-treated HBMEC-3 cells were fixed and 
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permeabilized before staining for p65 NF-κB. F) levels of nuclear localization of fluorescent 
NF-κB signal were quantified and normalized to nuclear area n = 5 independent 
experiments. G) representative x60 micrographs demonstrating p65 NF-κB (alexafluor 488) 
staining. Pixel intensity is illustrated by pseudo color of greyscale NF-kB staining using 
image J. scale bar = 10 µm. Data are mean ± SEM. *p < 0.05, **p < 0.001, & ***p < 0.0001 
vs. saline. #p < 0.05 & ##p < 0.001 vs. LPS.
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Figure 4. SFN reduces endothelial cell expression of adhesion molecules
Surface expression of A + B) E-selectin and C + D) VCAM-1 were investigated using 
immune-fluorescent staining of non-permeabilized HBMEC-3 cells following SFN pre-
treatment (1, 10 or 100 µM), and 4 h of saline or LPS (500 ng/ml) challenge. Staining was 
quantified as mean fluorescent intensity and normalized to account for cell number using the 
mean fluorescent intensity of DAPI staining. Scale bars = 10 µm. Data are mean ± SEM. n = 
3 independent experiments for each treatment group. *p < 0.05, **p < 0.001 & ***p < 0.0001 
vs. saline. #p < 0.05 vs. LPS.
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Figure 5. SFN induces Nrf2 activation and protects endothelial cell and neutrophils from 
oxidative stress
A) Nrf2 transcription factor activity in HBMEC-3 cells following LPS (500 ng/ml, 4 h) 
challenge and 24 h SFN pre-treatment as detected by Active moteif TransAM assay. ROS 
production as determined by CM-H2DCFDA fluorecence was asesed in SFN or saline or 
LPS treated B) HBMEC-3 cells or C) neutrophils. Data are mean ± SEM. n = 5. *p < 
0.05, **p < 0.001 & ***p < 0.0001 vs. saline. #p < 0.05 and ##p < 0.001 vs. LPS.
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Figure 6. Proposed mechanism of cerebrovascular neuroprotection elicited by SFN
SFN mediates its anti-inflammatory and anti-oxidant effects through Keap1/Nrf2 
transcriptional activation of the anti-oxidant system, and via the NFκB pathway. In 
particular, following systemic LPS administration, SFN treatment is able to 1) suppress 
VCAM-1 and E-selectin adhesion molecules, which in turn leads to a decrease in neutrophil 
endothelial cell interactions; 2) decrease pro-inflammatory cytokines and 3) decrease ROS 
production.
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